Oric Pharmaceuticals (ORIC) Cash & Equivalents (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Cash & Equivalents came in at $56.4 million in Q1 2026, up 14.31% YoY from $49.3 million in Q1 2025, and up 23.49% on a QoQ basis from $45.7 million in Q4 2025.
Oric Pharmaceuticals (ORIC) Cash & Equivalents (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Cash & Equivalents data on file, last reported at $56.4 million in Q1 2026.
- Quarterly Cash & Equivalents rose 14.31% year-over-year to $56.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.4 million (up 14.31% YoY) and the FY2025 annual result came in at $45.7 million, down 23.12% from the prior year.
- Cash & Equivalents improved to $56.4 million in Q1 2026, from $45.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $112.6 million in Q1 2022 to a low of $23.4 million in Q4 2023.
- A 5-year average of $56.3 million and a median of $49.8 million in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 87.94% — and 2024, when it surged 154.05%.
- Tracing ORIC's Cash & Equivalents over 5 years: stood at $66.8 million in 2022, then slumped by 65.01% to $23.4 million in 2023, then surged by 154.05% to $59.4 million in 2024, then slipped by 23.12% to $45.7 million in 2025, then rose by 23.49% to $56.4 million in 2026.
- The last three Cash & Equivalents figures came in at $56.4 million (Q1 2026), $45.7 million (Q4 2025), and $49.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | 37.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.48 Mn |
| Mar 31, 2026 | 56.40 Mn |
| Dec 31, 2025 | 45.67 Mn |
| Sep 30, 2025 | 49.67 Mn |
| Jun 30, 2025 | 75.86 Mn |
| Mar 31, 2025 | 49.33 Mn |
| Dec 31, 2024 | 59.41 Mn |
| Sep 30, 2024 | 44.23 Mn |
| Jun 30, 2024 | 49.83 Mn |
| Mar 31, 2024 | 56.36 Mn |
| Dec 31, 2023 | 23.38 Mn |
| Sep 30, 2023 | 26.24 Mn |
| Jun 30, 2023 | 103.68 Mn |
| Mar 31, 2023 | 58.99 Mn |
| Dec 31, 2022 | 66.84 Mn |
| Sep 30, 2022 | 29.08 Mn |
| Jun 30, 2022 | 49.08 Mn |
| Mar 31, 2022 | 112.64 Mn |
| Dec 31, 2021 | 226.01 Mn |
| Sep 30, 2021 | 241.13 Mn |